Arybzhanov DT1,3*, Gantsev ShKh2 and Sburov AR1,2
1The Head of the Department of Chemotherapy and Endovascular Oncology of Shymkent City Cancer Center, Candidate of Medical Science, Professor of the Department of Surgical Disciplines No. 2 of South-Kazakhstan Medical Academy, Kazakhstan
2Professor, the Head of the Department of Oncology with the courses of Institute of Postgraduate Education in Oncology and Pathological Anatomy of Bashkir State Medical University, Ufa, Russia
3Oncologist, Postgraduate Student of the Department of Oncology with the courses of Institute of Postgraduate Education in Oncology and Pathological Anatomy of Bashkir State Medical University, Ufa, Russia
*Corresponding Author: Arybzhanov DT, The Head of the Department of Chemotherapy and Endovascular Oncology of Shymkent City Cancer Center, Candidate of Medical Science, Professor of the Department of Surgical Disciplines No. 2 of South-Kazakhstan Medical Academy, Kazakhstan.
Received: July 21, 2022; Published: July 29, 2022
Nowadays, the technique of intra-arterial chemotherapy in primary patients with gastric cancer can be considered as an effective, low-toxic method of treatment. Preoperative intra-arterial chemotherapy may be the method of choice for improving the survival and quality of life of patients with gastric cancer.
Nowadays, results of the diagnosis and treatment of gastric cancer (GC) are still unsatisfactory. With the development of modern catheters and angiographic devices, regional chemotherapy in patients with gastric cancer has become more often used in clinical practice.
Goal of the research: Improving the response to treatment of patients with gastric cancer using regional intra-arterial chemotherapy (RIAC).
Materials and methods: There were analyzed short and long-term results of combination therapy of 110 patients with gastric cancer for the period of 2005-2020. The average age of patients was 59.2 ± 4.3 years old. The incidence of neoplastic process according to the TNM classification was as follows: T3N0M0 - 37 (33.63%) patients, T3N1M0 - 41 (37.27%) patients and T3N2M0 - 32 (29.1%) patients. Histologically, various forms of adenocarcinoma were diagnosed in all patients
All patients underwent the first stage of neoadjuvant intra-arterial chemotherapy (RIAC) according to the DPF scheme (Docetaxel 75mg/m2 + Cisplatin 75mg/m2 + Fluorouracil 1000mg/m2 on the 1st day), it comprised 2 cycles with an interval of 28 days, and then, there was performed surgery.
Results and their discussion: Short-term results of RIAC showed the effectiveness of treatment after 2 cycles of neoadjuvant intra-arterial regional chemotherapy; 93 (84.5%) patients showed partial regression, 17 (15.5%) patients showed stabilization of the process. These patients underwent radical surgery with the second stage of combination therapy - extended gastrectomy with D2 lymphodissection.The medicinal pathomorphosis of 1-2 grade was represented in 34 (30.9%) patients, pathomorphosis of the 3rd grade was represented in 38 (34.5%) patients, pathomorphosis of the 4th grade - 9 (8.1%) patients. The case follow-up showed the following results: 9 (8.1%) patients lived for 6 months, 63 (57.2%) patients lived for 12 months, 59 (53.3%) patients lived for 18 months, 57 (51.8%) patients lived for 24 months, 47 (42.7%) patients lived for 36 months, 41 (37.2%) patients lived for 48 months and 35 (31.8%) patients continue to live for 60 months or more. Median survival was 51.8 +1.5 months.
Conclusion: Neoadjuvant RIAC in the treatment of patients with gastric cancer was effective in 84.5% of patients. In 42.6% of patients, there was represented therapeutic pathomorphosis of 3-4 grade. The 3 and 5-year survival rates were 42.7% and 31.8%, respectively. Median survival was 51.8 +1.5 months
Keywords: Gastric Cancer; Intra-Arterial Chemotherapy; Surgical Treatment; Survival
Citation: Arybzhanov DT., et al. “Preoperative Transarterial Chemoinfusion in the Treatment of Patients with Gastric Cancer". Acta Acta Scientific Gastrointestinal Disorders 5.8 (2022): 58-61.
Copyright: © 2022 Arybzhanov DT., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.